Ono Pharmaceutical Co., Ltd.

TSE:4528 Rapport sur les actions

Capitalisation boursière : JP¥919.7b

Ono Pharmaceutical Résultats passés

Passé contrôle des critères 2/6

Ono Pharmaceutical has been growing earnings at an average annual rate of 16%, while the Pharmaceuticals industry saw earnings growing at 3.4% annually. Revenues have been growing at an average rate of 13.5% per year. Ono Pharmaceutical's return on equity is 12.1%, and it has net margins of 19.6%.

Informations clés

16.0%

Taux de croissance des bénéfices

17.2%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie3.4%
Taux de croissance des recettes13.5%
Rendement des fonds propres12.1%
Marge nette19.6%
Dernière mise à jour des bénéfices30 Sep 2024

Mises à jour récentes des performances passées

Recent updates

Ono Pharmaceutical Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Nov 03
Ono Pharmaceutical Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt

Aug 25
We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 04
Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Jun 24
There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Mar 04
Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Feb 27
Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Ventilation des recettes et des dépenses

Comment Ono Pharmaceutical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

TSE:4528 Recettes, dépenses et bénéfices (JPY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Sep 24484,29895,127108,209131,617
30 Jun 24500,331120,953101,792116,452
31 Mar 24502,672127,97797,389112,174
31 Dec 23498,070127,61193,791105,863
30 Sep 23489,199124,87591,302105,076
30 Jun 23460,481115,06488,400100,510
31 Mar 23447,187112,72386,64395,344
31 Dec 22428,951111,55582,77892,389
30 Sep 22403,98596,56879,40882,955
30 Jun 22380,72085,92276,89080,047
31 Mar 22361,36180,51974,11975,879
31 Dec 21345,78173,55875,88868,001
30 Sep 21332,88781,86674,45569,203
30 Jun 21321,73478,00371,37265,286
31 Mar 21309,28475,42566,61662,384
31 Dec 20302,05474,36462,47464,973
30 Sep 20293,88666,73761,27961,295
30 Jun 20293,35164,87062,82262,874
31 Mar 20292,42059,70465,19666,497
31 Dec 19290,73660,23366,77164,207
30 Sep 19293,24755,51067,52867,895
30 Jun 19291,37452,63367,54870,264
31 Mar 19288,63451,53968,00070,008
31 Dec 18284,46351,97869,04371,627
30 Sep 18284,78557,91967,96770,453
30 Jun 18272,16553,74667,13869,593
31 Mar 18261,83650,28466,35368,821
31 Dec 17256,52254,76064,97866,892
30 Sep 17248,51753,88463,96663,599
30 Jun 17246,95353,88762,84661,325
31 Mar 17244,79755,79360,66057,506
31 Dec 16236,71048,27057,39652,949
30 Sep 16207,70736,22553,70249,595
30 Jun 16183,34529,20649,85046,653
31 Mar 16160,28424,97942,62843,369
31 Dec 15140,92716,44938,70540,751
30 Sep 15143,69721,56837,11340,790
30 Jun 15139,66319,52136,24439,972
31 Mar 15135,77512,97640,82441,346
31 Dec 14137,59217,66342,57238,204
30 Sep 14133,92613,47441,29639,463
30 Jun 14137,14616,78739,68540,895
31 Mar 14143,24720,35036,90044,413
31 Dec 13145,94621,57435,55249,229

Des revenus de qualité: 4528 has high quality earnings.

Augmentation de la marge bénéficiaire: 4528's current net profit margins (19.6%) are lower than last year (25.5%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: 4528's earnings have grown by 16% per year over the past 5 years.

Accélération de la croissance: 4528's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Bénéfices par rapport au secteur d'activité: 4528 had negative earnings growth (-23.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (38.7%).


Rendement des fonds propres

ROE élevé: 4528's Return on Equity (12.1%) is considered low.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé